A total of 613 patients with FLT3-ITD AML undergoing allo-HSCT were enrolled in this study between January 2012 and June 2020, including 441 patients from the prospective studies and 172 from the retrospective studies (Fig. 1). The gene discussed is FLT3; the disease is acute myeloid leukemia.